The much-awaited Symbiotec Pharmalab IPO opened for subscription, August 24, 2026, with strong grey-market sentiment setting the stage for investor interest. The issue is currently commanding a GMP of around 41%, signalling expectations of a potentially strong listing gain.
The biopharmaceutical and biotechnology company is looking to raise Rs 1,757 crore through the public issue. The IPO comprises a fresh issue of 15 lakh shares worth Rs 150 crore and an offer for sale (OFS) of 1.63 crore shares aggregating to Rs 1,607 crore.
